Patent Issued for New HPV Treatment Program
Researchers are developing a vaginal insert to treat persistent high-risk HPV infections in women.
Updated on Sept. 28, 2026 in Cancer
Live Poll
Do you trust that biotech companies are successfully closing treatment gaps for common medical conditions?
On July 14, 2026, the U.S. Patent and Trademark Office issued a patent for a novel pharmaceutical composition designed to treat cervical pathologies related to human papillomavirus (HPV). San Diego-based Daré Bioscience is currently testing this investigational treatment in a Phase 2 clinical study.
Why it matters
There are currently no FDA-approved pharmacologic treatments for high-risk HPV infections, which affect approximately six million people in the U.S. annually. This new approach aims to provide a non-surgical, self-administered option for patients dealing with persistent infection.
The investigational treatment is currently undergoing a Phase 2 trial involving 100 participants. The study evaluates the antiviral activity and safety of the vaginal insert over a 21-day course of daily treatment, though these findings remain preliminary.
The players
Daré Bioscience
A San Diego-based biopharmaceutical company focused on developing therapies for women's reproductive health.
Douglas Pharmaceuticals Limited
The pharmaceutical company that owns the patent for the DARE-HPV compositions and licenses it to Daré Bioscience.
ARPA-H
A federal agency within the U.S. government that funds high-risk, high-reward biomedical and health research.
National Institute of Allergy and Infectious Diseases
The NIH institute responsible for conducting and funding research on infectious and immune-mediated diseases.
The details
The treatment, known as DARE-HPV, uses a fixed-dose formulation of the antiviral drugs lopinavir and ritonavir. Designed as a localized, self-administered vaginal insert, it aims to deliver medication directly to cervical tissues to address viral presence. The program is supported by $10 million in funding from ARPA-H and a $2.0 million award from the National Institute of Allergy and Infectious Diseases.
Timeline
July 14, 2026: The U.S. Patent and Trademark Office issued patent number 12,678,439.
September 28, 2026: Daré Bioscience announced the patent issuance.
2027: Topline results from the Phase 2 clinical study are expected.
2039: The earliest date for expected patent protection expiration.
Health Landscape
The development of DARE-HPV represents an attempt to fill a significant void in the current standard of care for persistent high-risk HPV. It sits at the intersection of ongoing efforts to move beyond surgical management of cervical pathologies toward targeted, localized antiviral therapies.
While this treatment remains investigational, those concerned about persistent HPV should maintain regular screening schedules as recommended by their physician. Discuss your specific cervical health history and any available management options with your doctor during your next visit.
The takeaway
The issuance of this patent marks a technical step forward for a program aimed at filling the gap in non-surgical HPV care. Patients should continue to rely on established preventive screenings until further results from the 2027 clinical trials become available.
Further reading
Learn more about the latest innovations in Cancer research and care.
More information
View the clinical study registry details for more information on the trial protocol.
Live Poll
Do you trust that biotech companies are successfully closing treatment gaps for common medical conditions?
